- Home
- TYRA vs COMM Comparison
TYRA vs COMM Comparison
Compare TYRA & COMM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYRA
- COMM
- Stock Information
- Founded
- TYRA 2018
- COMM 1976
- Country
- TYRA United States
- COMM United States
- Employees
- TYRA N/A
- COMM N/A
- Industry
- TYRA Biotechnology: Pharmaceutical Preparations
- COMM Radio And Television Broadcasting And Communications Equipment
- Sector
- TYRA Health Care
- COMM Technology
- Exchange
- TYRA Nasdaq
- COMM Nasdaq
- Market Cap
- TYRA 812.7M
- COMM 1.1B
- IPO Year
- TYRA 2021
- COMM 2013
- Fundamental
- Price
- TYRA $14.43
- COMM $5.16
- Analyst Decision
- TYRA Strong Buy
- COMM Sell
- Analyst Count
- TYRA 5
- COMM 5
- Target Price
- TYRA $31.00
- COMM $2.50
- AVG Volume (30 Days)
- TYRA 201.5K
- COMM 3.9M
- Earning Date
- TYRA 11-07-2024
- COMM 02-27-2025
- Dividend Yield
- TYRA N/A
- COMM N/A
- EPS Growth
- TYRA N/A
- COMM N/A
- EPS
- TYRA N/A
- COMM N/A
- Revenue
- TYRA N/A
- COMM $5,183,800,000.00
- Revenue This Year
- TYRA N/A
- COMM N/A
- Revenue Next Year
- TYRA N/A
- COMM N/A
- P/E Ratio
- TYRA N/A
- COMM N/A
- Revenue Growth
- TYRA N/A
- COMM 21.78
- 52 Week Low
- TYRA $11.24
- COMM $0.86
- 52 Week High
- TYRA $29.60
- COMM $7.19
- Technical
- Relative Strength Index (RSI)
- TYRA 42.39
- COMM 44.29
- Support Level
- TYRA $13.27
- COMM $5.14
- Resistance Level
- TYRA $14.77
- COMM $5.84
- Average True Range (ATR)
- TYRA 0.75
- COMM 0.40
- MACD
- TYRA 0.07
- COMM -0.06
- Stochastic Oscillator
- TYRA 50.19
- COMM 1.42
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).
About COMM CommScope Holding Company Inc.
CommScope Holding Co Inc is a provider of infrastructure solutions for communication, data center and entertainment networks. The company provides solutions for wired and wireless networks to enable service providers, including cable, telephone, data center and digital broadcast satellite operators and media programmers, to deliver media, voice, Internet Protocol (IP) data services and Wi-Fi to their subscribers and allow enterprises to experience constant wireless and wired connectivity across complex and varied networking environments. They have operating segments, which excludes our Home segment: Connectivity and Cable Solutions (CCS), Outdoor Wireless Networks (OWN), Networking, Intelligent Cellular and Security Solutions (NICS) and Access Network Solutions (ANS).